(Q48036553)

7 February 2018

title

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. (English)

1 reference

7 February 2018

1 reference

1 reference

Guido Ferrari

5

0 references

Julie McElrath

11

M Juliana McElrath

1 reference

7 February 2018

4

David Montefiori

1 reference

7 February 2018

17

Lindsey R Baden

1 reference

7 February 2018

Beryl A Koblin

14

Beryl A Koblin

1 reference

7 February 2018

Georgia D. Tomaras

2

Georgia D Tomaras

1 reference

7 February 2018

Sharon E Frey

16

Sharon Frey

1 reference

7 February 2018

Thomas G. Evans

19

Thomas Evans

1 reference

7 February 2018

author name string

Paul A Goepfert

1

1 reference

7 February 2018

Helen Horton

3

1 reference

7 February 2018

Mark Deers

6

1 reference

7 February 2018

Gerald Voss

7

1 reference

7 February 2018

Marguerite Koutsoukos

8

1 reference

7 February 2018

Louise Pedneault

9

1 reference

7 February 2018

Pierre Vandepapeliere

10

1 reference

7 February 2018

Paul Spearman

12

1 reference

7 February 2018

Jonathan D Fuchs

13

1 reference

7 February 2018

William A Blattner

15

1 reference

7 February 2018

Clayton Harro

18

1 reference

7 February 2018

NIAID HIV Vaccine Trials Network

20

1 reference

7 February 2018

language of work or name

English

0 references

publication date

10 August 2006

1 reference

7 February 2018

published in

Vaccine

1 reference

7 February 2018

volume

25

1 reference

7 February 2018

issue

3

1 reference

7 February 2018

page(s)

510-518

1 reference

7 February 2018

Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Challenges and opportunities for development of an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Progress toward an HIV vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human Subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Importance of the nef gene for maintenance of high virus loads and for development of AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Prevention of disease induced by a partially heterologous AIDS virus in rhesus monkeys by using an adjuvanted multicomponent protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Cellular uptake of the tat protein from human immunodeficiency virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Identifying epitopes of HIV-1 that induce protective antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Vaccination in humans generates broad T cell cytokine responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Helping the CD8(+) T-cell response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Viral immune evasion due to persistence of activated T cells without effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Immune control of HIV-1 after early treatment of acute infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

Neutralizing antibodies take a swipe at HIV in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.050

10.1016/J.VACCINE.2006.07.050

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

PubMed ID

17049679

1 reference

7 February 2018